Clinical trial
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple…
NCT00349778 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00349778 |
|---|---|
| Title | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma |
| Official title | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim |
| Enrollment | 102 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jul 10, 2006 |
| Last update posted | Dec 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: